NANT Homepage
NANT Homepage About Us How You Can Help NANT Trials Contact Us

Publications

Publications from studies of the NANT consortium as well as from research of investigators in the NCI Program Project "Biology and Therapy of High-Risk Neuroblastoma" are available for download from this site.

Please select from the drop-down menu below to view the list of available downloads for that year. Downloadable articles are linked in green. Please click or right-click and choose "Save As" to download them. Articles which are not yet available are not linked.

Publications are arranged in chronological order and alphabetically by last name.

Publications from 2000

  1. PDF icon  Anderson, C. P., Keshelava, N., Satake, N., Meek, W. H., and Reynolds, C. P.
    Synergism of buthionine sulfoximine and melphalan against neuroblastoma cell lines derived after disease progression. Med.Pediatr.Oncol., 35: 659-662, 2000.
  2. PDF icon  Keshelava, N., Zuo, J. J., Waidyaratne, N. S., Triche, T. J., and Reynolds, C. P.
    p53 mutations and loss of p53 function confer multidrug resistance in neuroblastoma. Med.Pediatr.Oncol., 35: 563-568, 2000.
  3. PDF icon  Keshelava, N., Groshen, S., and Reynolds, C. P.
    Cross-resistance of topoisomerase I and II inhibitors in neuroblastoma cell lines. Cancer Chemother.Pharmacol., 45: 1-8, 2000.
  4. PDF icon  Matthay, K. K. and Reynolds, C. P.
    Is there a role for retinoids to treat minimal residual disease in neuroblastoma? Br.J.Cancer, 83:1121-1123, 2000.
  5. PDF icon  Maurer, B. J., Melton, L., Billups, C., Cabot, M. C., and Reynolds, C. P.
    Synergistic cytotoxicity in solid tumor cell lines between N-(4- hydroxyphenyl)retinamide and modulators of ceramide metabolism. J.Natl.Cancer Inst., 92: 1897-1909, 2000.
  6. PDF icon  Reynolds, C. P. and Seeger, R. C.
    Neuroblastoma. In C. M. Haskell (ed.), Cancer Treatment, Fifth ed, pp. 1214-1236. Philadelphia: W.B. Saunders, 2000.
  7. PDF icon  Seeger, R. C., Reynolds, C. P., Gallego, R., Stram, D. O., Gerbing, R. B., and Matthay, K. K.
    Quantitative tumor cell content of bone marrow and blood as a predictor of outcome in stage IV neuroblastoma: a Children's Cancer Group Study. J.Clin.Oncol, 18: 4067-4076, 2000.

Publications from 2001

  1. PDF icon  Anderson, C. P., Seeger, R. C., Satake, N., Monforte-Munoz, H. L., Keshelava, N., Bailey, H.H., and Reynolds, C. P.
    Buthionine sulfoximine and myeloablative concentrations of melphalan overcome resistance in a melphalan-resistant neuroblastoma cell line. J.Pediatr.Hematol.Oncol., 23: 500-505, 2001.
  2. PDF icon  Keshelava, N., Zuo, J. J., Chen, P., Waidyaratne, S. N., Luna, M. C., Gomer, C. J., Triche, T. J., and Reynolds, C. P.
    Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res, 61:6185-6193, 2001.
  3. PDF icon  Metelitsa, L. S., Naidenko, O. V., Kant, A., Wu, H. W., Loza, M. J., Perussia, B., Kronenberg, M., and Seeger, R. C.
    Human NKT Cells Mediate Antitumor Cytotoxicity Directly by Recognizing Target Cell CD1d with Bound Ligand or Indirectly by Producing IL-2 to Activate NK Cells. J.Immunol., 167: 3114-3122, 2001.
  4. Reynolds, C. P. and Lemmons, R. S.
    Retinoid therapy of childhood cancer. Hematol.Oncol Clin.North Am., 15: 867-910, 2001.
  5. PDF icon  Reynolds, C. P. and Seeger, R. C.
    Detection of Minimal Residual Disease in Bone Marrow During or After Therapy as a Prognostic Marker for High-Risk Neuroblastoma. Am.J.Pediatr.Hematol.Oncol., 23: 150-152, 2001.
  6. PDF icon  Tang, H. R., Da Silva, A. J., Matthay, K. K., Price, D. C., Huberty, J. P., Hawkins, R. A., and Hasegawa, B. H.
    Neuroblastoma imaging using a combined CT scanner-scintillation camera and 131I-MIBG. J.Nucl.Med., 42: 237-247, 2001.
  7. PDF icon  Wang, H., Maurer, B. J., Reynolds, C. P., and Cabot, M. C.
    N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res, 61: 5102-5105, 2001.

Publications from 2002

  1. PDF icon  Anderson, C. P. and Reynolds, C. P.
    Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant., 30:135-140, 2002.
  2. PDF icon  Erdreich-Epstein, A., Tran, L.B., Bowman, N. N., Wang, H., Cabot, M.C., Durden, D.L., Vlckova, J., Reynolds, C. P., Stins, M.F., Groshen, S., Millard, M.
    Ceramide Signaling in Fenretinide-induced Endothelial Cell Apoptosis. The Journal of Biological Chemistry, 277:49531-49537, 2002.
  3. PDF icon  Ho R. Eggert A. Hishiki T. Minturn JE. Ikegaki N. Foster P. Camoratto AM. Evans AE. Brodeur GM.
    Resistance to chemotherapy mediated by TrkB in neuroblastomas. Cancer Research. 62:6462-6, 2002
  4. PDF icon  Houghton, P.J., Adamson, P.C., Blaney, S., Fine, H.A., Gorlick, R., Haber, M., Helman, L., Hirschfeld, S., Hollingshead, M.G., Israel, M.A., Lock, R.B., Maris, J.M., Merlino, G., Patterson, W., Reynolds, C.P., Shannon, K., Yu, A., Yu, J., Smith, M.A.
    Testing of New Agents in Childhood Cancer Preclinical Models: Meeting Summary, Clinical Cancer Research, 8:3646-3657, 2002.
  5. Wigginton J.M., Wiltrout R.H.
    IL-12/IL-2 combination cytokine therapy for solid tumours: translation from bench to bedside. Expert Opinion on Biological Therapy. 2:513-24, 2002.
  6. PDF icon  Yanik, G. A., Levine, J. E., Matthay, K. K., Sisson, J. C., Shulkin, B. L., Shapiro, B., Hubers, D., Spalding, S., Braun, T., Ferrara, J. L., and Hutchinson, R. J.
    Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J.Clin.Oncol, 20: 2142-2149, 2002.

Publications from 2003

  1. PDF icon  Haas-Kogan, D.A., Swift, P.S., Selch, M., Haase, G.M., Seeger, R.C., Gerbing, R.B., Stram, D.O., Matthay, K.K.
    Impact of Radiotherapy for High-Risk Neuroblastoma: A Children's Cancer Group Study. Int. J. Radiation Oncology Biol. Phys., 56: 28-39, 2003
  2. PDF icon  Jaboin J. Hong A. Kim CJ. Thiele CJ.
    Cisplatin-induced cytotoxicity is blocked by brain-derived neurotrophic factor activation of TrkB signal transduction path in neuroblastoma. Cancer Letters. 193:109-14, 2003.
  3. PDF icon  Keshelava, N., Tsao-Wei, D., Reynolds, C. P.
    Pyrazoloacridine Is Active in Multidrug-resistant Neuroblastoma Cell Lines with Nonfunctional p53. Clinical Cancer Research, 9:3492-3502, 2003.
  4. PDF icon  Matthay, K.K., Edeline, V., Lumbroso, J., Tanguy, M.L., Asselain, B. Zucker, J.M., Valteau-Couanet, D., Hartmann, O., Michon, J.
    Correlation of Early Metastatic Response by 123I-Metaiodobenzylguanidine Scintigraphy With Overall Response and Event-Free Survival in Stage IV Neuroblastoma. Journal of Clinical Oncology, 21: 2486-2491, 2003.
  5. PDF icon  Reynolds, C. P., Matthay, K. K., Villablanca, J. G., Maurer, B. J.
    Retinoid Therapy of High-Risk Neuroblastoma. Cancer Letters, 197:185-192, 2003.
  6. PDF icon  Sohara, Y., Shimada, H., Scadeng, M., Pollack, H., Yamada, S., Ye, W., Reynolds, C. P., and DeClerck, Y. A.
    Lytic Bone Lesions in Human Neuroblastoma Xenograft Involve Osteoclast Recruitment and Are Inhibited by Bisphosphonate. Cancer Research 63:3026-3031, 2003.
  7. PDF icon  Weiss, B., Vora, A., Matthay, K.K., Huberty, J., Hawkins, R.A.
    Secondary Myelodysplastic Syndrome and Leukemia Following 131I-Metaiodobenzylguanidine Therapy for Relapsed Neuroblastoma. Journal of Pediatric Hematology/Oncology, 25: 2003.
  8. PDF icon  Yang, B., Keshelava, N., Anderson, C.P. and Reynolds, C.P.
    Antagonism of Buthionine Sulfoximine Cytotoxicity for Human Neuroblastoma Cell Lines by Hypoxia Is Reversed by the Bioreductive Agent Tirapazamine. Cancer Research 63:1520-1526, 2003

Publications from 2004

  1. PDF icon  Adkins, E. S., Sawin, R., Gerbing, R. B., London, W. B., Matthay, K. K., and Haase, G. M.
    Efficacy of complete resection for high-risk neuroblastoma: a Children's Cancer Group study. J.Pediatr.Surg., 39: 931-936, 2004.
  2. PDF icon  Batra, S., Reynolds, C. P., and Maurer, B. J.
    Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators. Cancer Res., 64: 5415-5424, 2004.
  3. PDF icon  DuBois, S. G., Messina, J., Maris, J. M., Huberty, J., Glidden, D. V., Veatch, J., Charron, M., Hawkins, R., and Matthay, K. K.
    Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J.Clin.Oncol., 22: 2452-2460, 2004.
  4. Goldsby, R. E. and Matthay, K. K.
    Neuroblastoma : evolving therapies for a disease with many faces. Paediatr.Drugs, 6: 107-122, 2004.
  5. PDF icon  Hickeson, M. P., Charron, M., Maris, J. M., Brophy, P., Kang, T. I., Zhuang, H., Khan, J., and Nevrotski, T.
    Biodistribution of post-therapeutic versus diagnostic (131)I-MIBG scans in children with neuroblastoma. Pediatr.Blood Cancer, 42: 268-274, 2004.
  6. PDF icon  Reynolds, C. P., Maurer, B. J., and Kolesnick, R. N.
    Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett., 206: 169-180, 2004.
  7. Reynolds, C. P.
    Detection and treatment of minimal residual disease in high-risk neuroblastoma. Pediatr.Transplant., 8: 56-66, 2004.
  8. PDF icon  Vratilova, J., Frgala, T., Maurer, B. J., and Reynolds, C.P.
    Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues. J.Chromatogr.B Analyt.Technol.Biomed.Life Sci., 808: 125-130, 2004.
  9. PDF icon  Wagner, L. M., Crews, K. R., Iacono, L. C., Houghton, P. J., Fuller, C. E., McCarville, M. B., Goldsby, R. E., Albritton, K., Stewart, C. F., and Santana, V. M.
    Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin.Cancer Res., 10: 840-848, 2004.

Publications from 2005

  1. PDF icon  Grigoryan, R., Keshelava, N., Anderson, C., and Reynolds, C. P.
    In vitro testing of chemosensitivity in physiological hypoxia. Methods Mol.Med., 110: 87-100, 2005.
  2. PDF icon  Howard, J. P., Maris, J. M., Kersun, L. S., Huberty, J. P., Cheng, S. C., Hawkins, R. A., and Matthay, K. K.
    Tumor response and toxicity with multiple infusions of high dose 131I-MIBG for refractory neuroblastoma. Pediatr.Blood Cancer, 44: 232-239, 2005.
  3. PDF icon  Qualman,S.J., Bowen,J., Fitzgibbons,P.L., Cohn,S.L. and Shimada,H.
    Protocol for the examination of specimens from patients with neuroblastoma and related neuroblastic tumors, Arch.Pathol.Lab Med., 129: 874-883, 2005.
  4. PDF icon  Reynolds, C. P., Sun, B. C., DeClerck, Y. A., and Moats, R. A.
    Assessing growth and response to therapy in murine tumor models. Methods Mol.Med., 111: 335-350, 2005.
  5. PDF icon  Reynolds, C. P. and Maurer, B. J.
    Evaluating response to antineoplastic drug combinations in tissue culture models. Methods Mol.Med., 110: 173-183, 2005.
  6. PDF icon  Shimada,H.
    In situ neuroblastoma: an important concept related to the natural history of neural crest tumors, Pediatr.Dev.Pathol., 8: 305-306, 2005.
  7. PDF icon  Sohara,Y., Shimada,H. and DeClerck,Y.A.
    Mechanisms of bone invasion and metastasis in human neuroblastoma, Cancer Lett., 228: 203-209, 2005.
  8. PDF icon  Sohara, Y., Shimada, H., Minkin, C., Erdreich-Epstein, A., Nolta, J. A., and DeClerck, Y. A.
    Bone marrow mesenchymal stem cells provide an alternate pathway of osteoclast activation and bone destruction by cancer cells. Cancer Res., 65: 1129-1135, 2005.
  9. PDF icon  Wall,S.J., Werner,E., Werb,Z. and DeClerck,Y.A.
    Discoidin domain receptor 2 mediates tumor cell cycle arrest induced by fibrillar collagen, J.Biol.Chem., 280: 40187-40194, 2005.

Publications from 2006

  1. PDF icon  Judith G. Villablanca, Mark D. Krailo, Matthew M. Ames, Joel M. Reid, Gregory H. Reaman, and C. Patrick Reynolds
    Phase I Trial of Oral Fenretinide in Children With High-Risk Solid Tumors: A Report From the Children's Oncology Group (CCG 09709), J Clin Oncol 24:3423-3430, 2006.
  2. PDF icon  Chantrain,C.F., Henriet,P., Jodele,S., Emonard,H., Feron,O., Courtoy,P.J., DeClerck,Y.A. and Marbaix,E.
    Mechanisms of pericyte recruitment in tumour angiogenesis: a new role for metalloproteinases, Eur.J.Cancer, 42: 310-318, 2006.
  3. PDF icon  Grupp S.A., Cohn S.L., Wall D., Reynolds C.P.
    Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day, Pediatr. Blood Cancer, 46: 719-722, 2006.
  4. PDF icon  Jodele,S., Blavier,L., Yoon,J.M. and DeClerck,Y.A.
    Modifying the soil to affect the seed: role of stromal-derived matrix metalloproteinases in cancer progression, Cancer Metastasis Rev., 25: 35-43, 2006.
  5. PDF icon  Matthay,K.K.
    Is liver metastasis in neuroblastoma an indication for treatment reduction?, Pediatr.Blood Cancer, 46: 269-270, 2006.
  6. PDF icon  Matthay,K.K., Tan,J.C., Villablanca,J.G., Yanik,G.A., Veatch,J., Franc,B., Twomey,E., Horn,B., Reynolds,C.P., Groshen,S., Seeger,R.C. and Maris,J.M.
    Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study, J.Clin.Oncol., 24: 500-506, 2006.
  7. PDF icon  Messina,J.A., Cheng,S.C., Franc,B.L., Charron,M., Shulkin,B., To,B., Maris,J.M., Yanik,G., Hawkins,R.A. and Matthay,K.K.
    Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma, Pediatr.Blood Cancer, 2006.
  8. PDF icon  Mouchess,M.L., Sohara,Y., Nelson,M.D., Jr., DeClerck,Y.A. and Moats,R.A.
    Multimodal imaging analysis of tumor progression and bone resorption in a murine cancer model, J.Comput.Assist.Tomogr., 30: 525-534, 2006.
  9. PDF icon  Osenga,K.L., Hank,J.A., Albertini,M.R., Gan,J., Sternberg,A.G., Eickhoff,J., Seeger,R.C., Matthay,K.K., Reynolds,C.P., Twist,C., Krailo,M., Adamson,P.C., Reisfeld,R.A., Gillies,S.D. and Sondel,P.M.
    A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group, Clin.Cancer Res., 12: 1750-1759, 2006.
  10. PDF icon  Sano,H., Bonadio,J., Gerbing,R.B., London,W.B., Matthay,K.K., Lukens,J.N. and Shimada,H.
    International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age, Eur.J.Cancer, 42: 1113-1119, 2006.
  11. PDF icon  Wu,X., Kim,Y., Sun,B.C., Moore,J.D., Shaw,W.A. and Maurer,B.J.
    Liquid chromatography method for quantifying D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (D-threo-PPMP) in mouse plasma and liver, J.Chromatogr.B Analyt.Technol.Biomed.Life Sci., 837: 44-48, 2006.

Publications from 2007

  1. PDF icon  Frgala T, Kalous O, Proffitt RT, Reynolds CP
    A novel cytotoxicity assay with a 4 log dynamic range that identifies synergistic drug combinations. Molecular Cancer Therapeutics 6:886-897, 2007.
  2. Harned TM, Kalous O, Neuwelt A, Loera J, Ji L, Iovine P, Sposto R, Neuwelt EA, Reynolds CP
    Sodium Thiosulfate (STS) administered six hours after cisplatin does not compromise anti-neuroblastoma activity. Clinical Cancer Research (In Press, 2007).
  3. Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP
    Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents. J National Cancer Institute (In Press, 2007)
  4. PDF icon  Keshelava N, Davicioni E, Zesheng Wan Z, Ji L, Sposto R, Triche TJ, Reynolds CP
    Inhibition of histone deacetylase (HDAC) 1, a drug target identified by expression profiling, sensitizes multi-drug-resistant neuroblastoma cell lines to cytotoxic agents. J National Cancer Institute 99:1107-19, 2007.
  5. PDF icon  Maurer BJ, Kalous O, Yesair DW, Wu X, Vratilova J, Maldonado V, Khankaldyyan V, Frgala T, Sun BC, McKee RT, Burgess SW, Shaw WA, Reynolds CP
    Improved oral delivery of N-(4-hydroxyphenyl)retinamide with novel LYM-X-SORBTM organized lipid complex in mice. Clinical Cancer Research 13:3079-3086, 2007.
  6. PDF icon  Peng H, Sohara Y, Moats RA, Nelson MD Jr, Groshen SG, Ye W, Reynolds CP, DeClerck YA
    The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and ras-mediated tumor cell survival and proliferation. Cancer Research 67:9346-55, 2007.
  7. Song L, Ara T, Wu HW, Woo CW, Reynolds CP, Seeger RC, DeClerck YA, Thiele CJ, Richard Sposto R, Metelitsa LS
    MYCN oncogene negatively regulates localization of Va24-invariant natural killer T cells to the disease site in neuroblastoma. J Clinical Investigation (In Press, 2007)

Publications from 2009

  1. PDF icon  Matthay KK, Quach A, Huberty J, Franc BL, Hawkins RA, Jackson H, Groshen S, Shusterman S, Yanik G, Veatch J, Brophy P, Villablanca JG, Maris JM
    Iodine-131--metaiodobenzylguanidine double infusion with autologous stem-cell rescue for neuroblastoma: a new approaches to neuroblastoma therapy phase I study. J.Clin.Oncol. 2009 Mar 1;27 (7):1020-5. PMCID:PMC2738616
  2. PDF icon  Wagner LM, Villablanca JG, Stewart CF, Crews KR, Groshen S, Reynolds CP, Park JR, Maris JM, Hawkins RA, Daldrup-Link HE, Jackson HA, Matthay KK
    Phase I trial of oral irinotecan and temozolomide for children with relapsed high-risk neuroblastoma: a new approach to neuroblastoma therapy consortium study. J.Clin.Oncol. 2009 Mar 10;27(8):1290-6. PMCID:PMC2667827
  3. PDF icon  Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, Jackson HA, Mari AC, Carlson D, Maris J, Hawkins R, Matthay KK
    Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J.Clin.Oncol. 2009 Nov 10;27(32):5343-9. PMCID:PMC2773221

Publications from 2010

  1. PDF icon  Ara T, Declerck YA
    Interleukin-6 in bone metastasis and cancer progression. Eur J Cancer, 2010. PMCID: PMC2917917
  2. PDF icon  Bergfeld SA, DeClerck YA
    Bone marrow-derived mesenchymal stem cells and the tumor microenvironment. Cancer Metastasis Rev, 2010. PMID: 20411303
  3. PDF icon  Cai W, Maldonado NV, Cui W, Harutyunyan N, Ji L, Sposto R, Reynolds CP, Keshelava N
    Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models. Br J Cancer, 2010. PMCID: 2990610
  4. PDF icon  Delgado DC, Hank JA, Kolesar J, Lorentzen D, Gan J, Seo S, Kim K, Shusterman S, Gillies SD, Reisfeld RA, Yang R, Gadbaw B, DeSantes KB, London WB, Seeger RC, Maris JM, Sondel PM
    Genotypes of NK cell KIR receptors, their ligands, and Fcgamma receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res, 2010. PMCID: 2999644
  5. PDF icon  Gustafson WC, Weiss WA
    Myc proteins as therapeutic targets. Oncogene, 2010.PMCID: 2904682
  6. PDF icon  Huang JM, Sheard MA, Ji L, Sposto R, Keshelava N
    Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53. Mol Cancer Ther, 2010. PMID: 21159612
  7. PDF icon  Lee CL, Wahnishe H, Sayre GA, Cho HM, Kim HJ, Hernandez-Pampaloni M, Hawkins RA, Dannoon SF, VanBrocklin HF, Itsara M, Weiss WA, Yang X, Haas-Kogan DA, Matthay KK, Seo Y
    Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET. Med Phys, 2010.PMCID: PMC2937055

Publications from 2011

  1. PDF icon  Chesler L, Weiss WA
    Genetically engineered murine models-contribution to our understanding of the genetics, molecular pathology and therapeutic targeting of neuroblastoma. Seminars in cancer biology, 2011.PMID: 21958944
  2. PDF icon  Cooper J, Hwang K, Singh H, Wang D, Reynolds CP, Curley R, Williams S, Maurer B, and Kang M
    Fenretinide Metabolism in Humans and Mice: Utilizing Pharmacologic Modulation of its Metabolic Pathway to Increase Systemic Exposure. British Journal of Pharmacology, 2011. PMCID: 3144539
  3. PDF icon  Fang H, Harned TM, Kalous O, Maldonado V, DeClerck YA, Reynolds CP
    Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma. Clin Cancer Res, 2011.PMID: 21933888
  4. PDF icon  Gustafson WC, Matthay KK
    Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma. Expert Rev Neurother, 2011. PMID: 21955198
  5. PDF icon  Minturn JE, Evans AE, Villablanca JG, Yanik GA, Park JR, Shusterman S, Groshen S, Hellriegel ET, Bensen-Kennedy D, Matthay KK, BrodeurGM and Maris JM
    Phase I Trial of Lestaurtinib for Children with Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Consortium Study. Cancer Chemotherapy and Pharmacology, 2011. PMID: 21340605
  6. PDF icon  More SS, Itsara M, Yang X, Geier EG, Tadano MK, Seo Y, Vanbrocklin HF, Weiss WA, Mueller S, Haas-Kogan DA, Dubois SG, Matthay KK,Giacomini KM
    Vorinostat increases expression of functional norepinephrine transporter in neuroblastoma in vitro and in vivo model systems. Clin Cancer Res, 2011. PMCID: 3247296
  7. <
  8. PDF icon  Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley M, Weiss WA, Matthay KK, Davidoff AM, DuBois SG, Haas-Kogan DA
    Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms. Cancer Letters 2011.
  9. PDF icon  Quach A, Ji L, Mishra V, Sznewajs A, Veatch J, Huberty J, Franc B, Sposto R, Groshen S, Denice Wei D, Fitzgerald P, Maris JM, Yanik G, Hawkins RA, Villablanca JG, Matthay KK
    Thyroid and Hepatic Function After High Dose 131I-Metaiodobenzylguanidine (131I-MIBG) Therapy for Neuroblastoma. Pediatr Blood Cancer. Feb;56(2):191-201, 2011. PMID: 20830775
  10. PDF icon  Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, Daldrup-Link HE, Marachelian A, Skerjanec A, Park JR, Katzenstein H, Matthay KK, Blaney SM, Villablanca JG
    A phase I study of zoledronic acid and low-dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatr Blood Cancer, 2011.PMCID: 3117015
  11. PDF icon  Seeger RC
    Immunology and immunotherapy of neuroblastoma. Seminars in cancer biology, 2011. PMCID: PMC3658311

Publications from 2012

  1. PDF icon  Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA.
    Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Science translational medicine. 2012;4(115):115ra3.
  2. PDF icon  DuBois SG, Chesler L, Groshen S, Hawkins R, Goodarzian G, Shimada H, Yanik G, Tagen M, Stewart C, Mosse YP, Maris JM, Tsao-Wei D, Marachelian A, Villablanca1 JG, Matthay KK
    Phase I Study of Vincristine, Irinotecan, and 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. Journal of Clinical Oncology, 2012.
  3. PDF icon  Matthay KK, George RE, Yu AL
    Promising therapeutic targets in neuroblastoma. Clinical Cancer Research, May 15, 2012.
  4. PDF icon  Matthay KK, Weiss B, Villablanca JG, Maris JM, Yanik GA, Dubois SG, Stubbs J, Groshen S, Tsao-Wei D, Hawkins R, Jackson H, Goodarzian F, Daldrup-Link H, Panigrahy A, Towbin A, Shimada H, Barrett J, Lafrance N, Babich J
    Dose Escalation Study of No-Carrier-Added 131I-Metaiodobenzylguanidine for Relapsed or Refractory Neuroblastoma: New Approaches to Neuroblastoma Therapy Consortium Trial. J Nucl Med, 2012. PMID: 22700000
  5. PDF icon  Seo Y, Gustafson WC, Dannoon SF, Nekritz EA, Lee CL, Murphy ST, VanBrocklin HF, Hernandez-Pampaloni M, Haas-Kogan DA, Weiss WA, Matthay KK
    Tumor dosimetry using [124I]m-iodobenzylguanidine microPET/CT for [131I]m-iodobenzylguanidine treatment of neuroblastoma in a murine xenograft model. Mol Imaging Biol, 2012. PMCID: PMC3369020
  6. PDF icon  Silverman AM, Nakata R, Shimada H, Sposto R, DeClerck YA
    A galectin-3-dependent pathway upregulates interleukin-6 in the microenvironment of human neuroblastoma. Cancer Res, 2012. PMCID: PMC3815584
  7. PDF icon  Yang F, Jove V, Buettner R, Xin H, Wu J, Wang Y, Nam S, Xu Y, Ara T, Declerck YA, Seeger R, Yu H, Jove R
    Sorafenib inhibits endogenous and IL-6/S1P induced JAK2-STAT3 signaling in human neuroblastoma, associated with growth suppression and apoptosis. Cancer Biol Ther, 2012. PMID: 22406995

Publications from 2013

  1. PDF icon  Ara T, Nakata R, Sheard MA, Shimada H, Buettner R, Groshen SG, Ji L, Yu H, Jove R, Seeger RC, DeClerck YA
    Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastoma. Cancer Res, 2013. PMCID: 3740971
  2. PDF icon  Fang H, Declerck YA
    Targeting the tumor microenvironment: from understanding pathways to effective clinical trials. Cancer Res, 2013. PMCID: 3815577
  3. PDF icon  Huang M, Weiss WA
    Neuroblastoma and MYCN. Cold Spring Harb Perspect Med, 2013. PMCID: PMC3784814
  4. PDF icon  Liu Y, Wu HW, Sheard MA, Sposto R, Somanchi SS, Cooper LJ, Lee DA, Seeger RC
    Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy. Clin Cancer Res, 2013. PMCID: 3658308
  5. PDF icon  Maurer BJ, Kang MH, Villablanca JG, Janeba J, Groshen S, Matthay KK, Sondel PM, Maris JM, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Hasenauer B, Reynolds CP, Marachelian A.
    Phase I trial of fenretinide delivered orally in a novel organized lipid complex in patients with relapsed/refractory neuroblastoma: A report from the new approaches to neuroblastoma therapy (NANT) consortium. Pediatric blood & cancer, 2013. PMCID: 4066886
  6. PDF icon  Mueller S, Bhargava S, Molinaro AM, Yang X, Kolkowitz I, Olow A, Wehmeijer N, Orbach S, Chen J, Matthay KK, Haas-Kogan DA
    Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Res, 2013. PMCID: 3684561
  7. PDF icon  Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, McDermott U, Benes CH, Kung AL, Weiss WA, Bradner JE, Stegmaier K
    Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov, 2013. PMID: 23430699
  8. PDF icon  Sheard MA, Asgharzadeh S, Liu Y, Lin TY, Wu HW, Ji L, Groshen S, Lee DA, Seeger RC
    Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cells. J Immunother, 2013. PMCID: 4064791
  9. PDF icon  Teitz T, Inoue M, Valentine MB, Zhu K, Rehg JE, Zhao W, Finkelstein D, Wang YD, Johnson MD, Calabrese C, Rubinstein M, Hakem R, Weiss WA, Lahti JM
    Th-MYCN mice with caspase-8 deficiency develop advanced neuroblastoma with bone marrow metastasis. Cancer Res, 2013. PMCID: 3702642
  10. PDF icon  Wong T, Matthay KK, Boscardin WJ, Hawkins RA, Brakeman PR, DuBois SG.
    Acute changes in blood pressure in patients with neuroblastoma treated with (1)(3)(1)I-metaiodobenzylguanidine (MIBG). Pediatr Blood Cancer, 2013. PMID: 23613447
  11. PDF icon  Xu Y, Sun J, Sheard MA, Tran HC, Wan Z, Liu WY, Asgharzadeh S, Sposto R, Wu HW, Seeger RC.
    Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFbeta1. Cancer Immunol Immunother, 2013. PMCID: 3907789

Publications from 2014

  1. PDF icon  Bergfeld SA, Blavier L, DeClerck YA
    Bone marrow-derived mesenchymal stromal cells promote survival and drug resistance in tumor cells. Mol Cancer Ther, 2014.PMCID: 4000239
  2. PDF icon  Gustafson WC, Meyerowitz JG, Nekritz EA, Chen J, Benes C, Charron E, Simonds EF, Seeger R, Matthay KK, Hertz NT, Eilers M, Shokat KM, Weiss WA
    Drugging MYCN through an allosteric transition in Aurora kinase A. Cancer Cell, 2014. PMCID: 4160413
  3. PDF icon  Huang SY, Bolch WE, Lee C, Van Brocklin HF, Pampaloni MH, Hawkins RA, Sznewajs A, DuBois SG, Matthay KK, Seo Y
    Patient-Specific Dosimetry Using Pretherapy [I]m-iodobenzylguanidine ([ I]mIBG) Dynamic PET/CT Imaging Before [ I]mIBG Targeted Radionuclide Therapy for Neuroblastoma. Mol Imaging Biol, 2014. PubMed PMID: 25145966
  4. PDF icon  Kang MH, Villablanca JG, Bender JL, Matthay KK, Groshen S, Sposto R, Czarnecki S, Ames MM, Reynolds CP, Marachelian A, Maurer BJ
    Probable fatal drug interaction between intravenous fenretinide, ceftriaxone, and acetaminophen: a case report from a New Approaches to Neuroblastoma (NANT) Phase I study. BMC Res Notes. 2014, 2014/04/23.
  5. PDF icon  Marshall GM, Carter DR, Cheung BB, Liu T, Mateos MK, Meyerowitz JG, Weiss WA
    The prenatal origins of cancer. Nat Rev Cancer, 2014. PMCID:4041218
  6. PDF icon  Solari V, Borriello L, Turcatel G, Shimada H, Sposto R, Fernandez GE, Asgharzadeh S, Yates EA, Turnbull JE, DeClerck YA
    MYCN-dependent expression of sulfatase-2 regulates neuroblastoma cell survival. Cancer Res, 2014. PMCID:4216758

Publications from 2015

  1. PDF icon  Chen J, Weiss WA
    Alternative splicing in cancer: implications for biology and therapy. Oncogene, 2015. PubMed PMID: 24441040
  2. PDF icon  DuBois S, Allen S, Bent M, Hilton J, Hollinger F, Hawkins R, Courtier J, Mosse Y, Matthay K
    Phase I/II Study of 131 I-MIBG with Vincristine and Five Days of Irinotecan for Advanced Neuroblastoma. British Journal of Cancer, 2015. PMCID: 4333502
  3. PDF icon  DuBois SG, Groshen S, Park JR, Haas-Kogan DA, Yang X, Geier E, Chen EC, Giacomini KM, Weiss B7, Cohn SL, Granger M, Yanik GA, Hawkins R1, Courtier J, Jackson HA, Goodarzian F, Shimada H, Czarnecki S, Tsao-Wei DD, Villablanca JG, Marachelian A, Matthay KK
    Phase 1 Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy (NANT) Trial. Clinical Cancer Research. 2015
  4. PDF icon  HaDuong J, Blavier L, Baniwal S, Frenkel B, Malvier J, Sposto R, DeClerck Y
    HaDuong J, Blavier L, Baniwal S, Frenkel B, Malvier J, Sposto R, DeClerck Y. Interaction between bone marrow stromal cells and neuroblastoma cells leads to a VEGFA-mediated osteoblastogenesis. Int JCancer, 2015.
  5. PDF icon  Yanik G, Villablanca J, Maris J, Weiss W, Groshen S, Marachelian A, Park J, Hawkins R, Shulkin B, Jackson H, Goodarzian F, Shimada H, Courtier J, Hutchinson R, Haas- Kogan D, Hasenauer C, Czaernecki S, Tsao-Wei D, Katzenstein H, Matthay K
    131 I-Metaiodobenzylguanidine with Intensive Chemotherapy and Autologous Stem Cell Transplant for High Risk Neuroblastoma. A New Approaches to Neuroblastoma Therapy (NANT) Phase II Study. Biology of Blood and Bone Marrow Tranplant, 2015.